Group 1 - The core point of the article is that Stone Pharmaceutical Group (01093) has seen its stock price increase by over 3%, currently trading at 10.58 HKD with a transaction volume of 526 million HKD, following the announcement of the approval for clinical trials of its drug SYH2066 by the National Medical Products Administration of China [1] Group 2 - The drug SYH2066 is a new chemical entity developed by the company, targeting respiratory syncytial virus (RSV) and is classified as a Class 1 new drug [1] - The approved indication for SYH2066 is for the treatment of respiratory infections caused by RSV, with preclinical studies indicating good oral bioavailability and significant reduction of RSV viral load in animal models, along with a high safety profile [1] - Currently, there are no small molecule drugs targeting RSV available in the domestic and international markets, positioning SYH2066 as a potentially effective treatment option with high clinical development value [1]
石药集团涨超3% SYH2066片在中国获临床试验批准